Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Operating Leases (2018 - 2023)

Ascendis Pharma A (ASND) has disclosed Operating Leases for 6 consecutive years, with $91.0 million as the latest value for Q4 2023.

  • Quarterly Operating Leases fell 6.48% to $91.0 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $91.0 million through Dec 2023, down 6.48% year-over-year, with the annual reading at $91.0 million for FY2023, 6.48% down from the prior year.
  • Operating Leases hit $91.0 million in Q4 2023 for Ascendis Pharma A, down from $97.3 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $112.1 million in Q4 2021 to a low of $40.5 million in Q4 2019.
  • Historically, Operating Leases has averaged $88.5 million across 5 years, with a median of $97.3 million in 2022.
  • Biggest five-year swings in Operating Leases: skyrocketed 150.37% in 2020 and later dropped 13.15% in 2022.
  • Year by year, Operating Leases stood at $40.5 million in 2019, then surged by 150.37% to $101.5 million in 2020, then rose by 10.43% to $112.1 million in 2021, then dropped by 13.15% to $97.3 million in 2022, then dropped by 6.48% to $91.0 million in 2023.
  • Business Quant data shows Operating Leases for ASND at $91.0 million in Q4 2023, $97.3 million in Q4 2022, and $112.1 million in Q4 2021.